EarningsQ2 2026 Earnings Report
MX:CI Q2 2026 EPS Results
Actual EPS$141.29
Consensus EPS$137.95
Beat/MissBeat by +$3.34
One Year Ago EPS$130.76
MX:CI Q2 2026 Revenue Results
Actual Revenue$1.30T
Expected Revenue$1.27T
Beat/MissBeat by +$26.45B
YoY Revenue Growth+6.50%
Earnings Announcement Details
QuarterQ2 2026
Date07/30/2026
TimeBefore Open
Conference CallThursday, July 30, 2026
MX:CI Upcoming Earnings
Cigna's next earnings date is estimated for October 29, 2026, based on past reporting schedules.
Q2 2026 Earnings Call Audio
MX:CI Q2 2026 Earnings Call
0:00 / 0:00
Q2 2026 Earnings Slide Deck
No slide deck is available for this earnings event.
Q2 2026 Earnings Call Summary
Earnings Call Sentiment|Positive
The call conveyed strong operational and financial momentum driven by specialty drug growth, Evernorth and Cigna Healthcare outperformance, AI-enabled clinical initiatives with measurable outcomes, solid revenue and EPS beats, and an upgraded full-year EPS outlook. Offsetting items include PBS earnings pressure from transition investments and economic shifts due to biosimilars, moderating GLP-1 utilization, persistently elevated medical cost trends, IDR-related affordability concerns, and one-time special charges. Overall, the positive drivers (revenue growth, margin gains in Specialty, upgraded guidance, retention/new-business strength, AI initiatives) materially outweigh the manageable challenges described.Company Guidance
Strong Q2 Financial Results
Total revenues of $71.7 billion and adjusted earnings per share of $7.78 in Q2; adjusted after-tax earnings of $2.1 billion for the quarter. Company delivered results ahead of expectations across the enterprise.
Raised Full-Year Guidance
Increased full-year 2026 adjusted earnings per share outlook to at least $30.45, reflecting strong first-half performance while maintaining a prudent view of the environment.
Evernorth Revenue Growth and Specialty Strength
Evernorth revenues grew 6% year-over-year to $61.5 billion; pretax adjusted earnings for Evernorth were $1.7 billion. Specialty & Care Services delivered pretax adjusted earnings of $1.1 billion, up 22% year-over-year, driven by specialty utilization growth, stronger biosimilar and specialty-generic adoption and operating efficiencies.
Cigna Healthcare Growth and Profitability
Cigna Healthcare revenues grew 10% year-over-year to $11.8 billion and pretax adjusted earnings grew 17% year-over-year to $1.3 billion. Medical care ratio (MCR) was 84.5% for the quarter, slightly better than expectations. U.S. employer membership growth and disciplined pricing contributed to results.
Rapid Adoption of Biosimilars / Specialty Generics
Faster-than-expected adoption of biosimilars and specialty generics improved affordability and contributed favorably to earnings; specialty generic penetration exceeded 80% for newer products in the quarter.
AI and Technology Initiatives Producing Measurable Outcomes
New programs (Pharmacy Forward, AI-enabled care coordination) expected to cut time-to-therapy in half and reduce clinician documentation time by up to 50%. Predictive/AI models can expand personalized clinical support to ~20% more customers; customers engaging in programs reduce medical costs by ~ $2,000 per year on average and have seen a 42% reduction in avoidable inpatient stays.
Strong PBM Retention and Selling Season Momentum
Pharmacy Benefit Services closed 2026 with over 97% retention and preliminary 2027 indicators also mid-90s+; total new business secured for 2027 is above the prior two selling seasons combined, indicating strong pipeline momentum for PBS and Signature interest.
Capital Management and Share Repurchases
Repurchased ~900,000 shares for approximately $250 million in Q2. Debt-to-capitalization was 42.8% as of June 30 with expectation to finish the year closer to 40%. Company expects approximately $9 billion of operating free cash flow for the year, mostly back-half weighted.
MX:CI Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed